Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

QCQingqing CaiSun Yat-sen UniversityHYHang YangHenan Cancer HospitalYJYirong JiangFirst Affiliated Hospital of Xi'an Jiaotong University

Discussion

Loading...

Member takes

Overview

Retrospective study reveals improved progression-free survival in DE-DLBCL with zanubrutinib plus R-CHOP, highlighting better treatment outcomes.

Key Points

  • To evaluate the real-world efficacy of zanubrutinib combined with R-CHOP in treating double-expressor DLBCL.
  • Conducted a multicenter, retrospective study
  • Included 281 DE-DLBCL patients treated with R-CHOP or ZR-CHOP
  • Used immunohistochemistry for diagnosis; response evaluated with PET-CT
  • Performed propensity score matching to ensure comparable groups
  • ZR-CHOP group showed significantly improved progression-free survival (PFS) rates at 1, 2, and 3 years compared to R-CHOP
  • Overall survival (OS) rates were also higher in the ZR-CHOP group at 1, 2, and 3 years
  • Neutropenia was the most common adverse event, affecting 29.8% of patients in the ZR-CHOP group
  • Complete remission rates were comparable between treatment groups, but ZR-CHOP had longer follow-up times

Cite This Study

Cai et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e290https://doi.org/10.1182/blood-2025-7202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study2026
  2. 2Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).2024
  3. 3Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL2026
  4. 4Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  5. 5Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025